The kit arrives in the mail, sits on a counter for a few weeks, and roughly one person in three never sends it back. On 20 August 2026, a Swedish study of 376,511 people put a number on what that missed errand costs: among people who actually complete the at-home stool test, the risk of dying from colorectal cancer falls by 43%.
None of this is new information about the disease itself — our guide to colorectal cancer, its symptoms and screening already covers the fundamentals. It answers a much more practical question, the one running through the mind of whoever is holding the envelope: does this little plastic tube actually do anything?
What the 20 August 2026 study found
Researchers at Karolinska Institutet and Umeå University followed residents of Stockholm and Gotland who were invited to screening between 2008 and 2012, tracking them for up to 14 years. Those two regions started routine screening early, which is why the follow-up is unusually long. Over the whole period, 1,668 colorectal cancer deaths were recorded.
The paper, published in JAMA Network Open, separates two things people routinely conflate. Being invited to screening was associated with a 26% lower risk of dying from the disease. Actually taking the test was associated with a 43% lower risk. The gap between those two numbers is precisely the people who receive a kit and never use it.
Earlier evaluations of the same program reported only a 14% reduction. The difference is not a better test but a statistical correction: the authors accounted for the fact that some people in the comparison group ended up being screened anyway, which had been diluting the measured benefit. They are careful to note that these adjustments leave some uncertainty in place.
Qué mide realmente la prueba
The test used in Sweden, and the one most widely used in the United States, is a fecal immunochemical test, or FIT. It looks for neither cancer cells nor DNA. It looks for human hemoglobin — blood invisible to the naked eye — using antibodies that bind to it. Polyps and tumors bleed a little, on and off, long before they cause any symptom. That trace of blood is what the test catches.
| Característica | Stool-based FIT | Qué significa para ti |
|---|---|---|
| A quién va dirigido | Average-risk adults, ages 45 to 75 | No symptoms, no prior polyps or IBD |
| How often | Cada año | Repetition is where the benefit comes from |
| Ejemplo | One stool sample, collected at home | No diet change and no bowel prep |
| What is measured | Hemoglobin concentration in stool | Reported as positive or negative, not as a number to interpret |
| If positive | Colonoscopy, ideally within 6 months | The follow-up is what completes the screening |
The positivity threshold is not a biological boundary. It is a public health dial. Lowering it would catch more lesions but send far more people to colonoscopy; raising it does the reverse. It is a trade-off, not a laboratory truth — which is one reason a FIT result is reported as positive or negative rather than as a value you are expected to read yourself.
A positive result is not a cancer diagnosis
This is where worry runs highest and is least warranted. A positive test means blood was found, and nothing more. Among people who go on to colonoscopy, most do not turn out to have cancer. Many have a polyp — which is removed during the same procedure, meaning screening did not detect a cancer so much as prevent one. In a large share of cases the colonoscopy finds nothing abnormal at all.
Plenty of harmless things make a bowel bleed: hemorrhoids, a small fissure, inflammation. Our pages on black specks in stool and what they mean y en normal and abnormal changes in stool consistency walk through those situations.
Registry data published in 2024 adds a wrinkle worth knowing: how often a positive stool test leads to a negative colonoscopy depends partly on the endoscopist. Among the highest-performing endoscopists, an adenoma was found in roughly 63% of colonoscopies done after a positive FIT. A normal result from a careful examination is genuinely reassuring; the quality of the follow-up matters as much as the test itself.
Slow digestive bleeding often shows up first on a routine blood panel, as unexplained anemia ferropénica o un nivel bajo de ferritina. In an adult over 45, that combination always deserves a look at the gut.
Latest scientific advances, in plain language
Based on the literature indexed in PubMed and in the Consensus database, four findings from the past three years put the Swedish result in context.
First: repeating the test matters more than perfecting it. A 2024 systematic review pooling 68 studies found that adding a second sample within the same screening episode cut the number of missed cancers by at least half, at the cost of a modest rise in positive results. A single test is imperfect; a test repeated on schedule becomes formidable.
Second: a run of negative tests is not a reason to stop. A 2026 study in the journal Gut, covering 2.81 million people across seven screening rounds, found that the first round yields the highest detection rates, after which results settle at a lower but still clinically meaningful level. The authors state plainly that stopping screening after a sequence of normal tests is not justified.
Third: participation, not technology, is the real lever. The Spanish COLONPREV trial, published in The Lancet in 2025 and covering 57,404 people, compared inviting people to colonoscopy against inviting them to FIT. After ten years, colorectal cancer mortality was equivalent — even though colonoscopy is by far the more powerful examination. The reason is simple: far more people said yes to the test they could do at home.
Fourth: blood tests are not yet a replacement. The American Cancer Society’s 2026 guideline update finds that blood-based screening tests detect advanced precancerous lesions and stage I cancers less well than stool-based options, and recommends them only for people who decline or do not complete a preferred test. Our article on the blood test for colon cancer covers that comparison in detail.
What you can do this week
If you are between 45 and 75 and a kit is sitting somewhere in your home, the useful action takes about ten minutes. One sample, no dietary changes, no preparation, prepaid return envelope. If you have no kit, ask at your next primary care visit — mailed FIT outreach is standard practice in most US health systems, and a randomized trial published in JAMA in 2025 found that a default mailed kit produced higher screening completion in adults aged 45 to 49 than asking them to choose between options.
Two situations call for something different. If you have a personal or family history of polyps, colorectal cancer, or inflammatory bowel disease, a stool test is not your screening pathway — you need colonoscopy-based surveillance on a schedule matched to your risk. And if you have symptoms such as visible bleeding, unexplained weight loss, or a lasting change in bowel habits, do not wait for the next screening cycle. Screening is designed for people without symptoms. Our pages on los resultados de calprotectina fecal y en stool testing for persistent diarrhea help place those signs.
Preguntas frecuentes
Is the at-home stool test reliable?
Taken once, it misses a share of lesions — that is the price of an examination simple enough that most people will actually do it. Its power comes from repetition on schedule, which is exactly what the fourteen-year Swedish follow-up demonstrates. A negative test today never removes the need for the next one.
My test came back positive. Should I panic?
A positive result warrants a prompt colonoscopy, not panic. Most follow-up colonoscopies do not find cancer; many find a polyp that is removed on the spot, and a substantial share find nothing at all. The single most important thing is to schedule the colonoscopy, ideally within six months.
Do I need to change my diet before the test?
No. A fecal immunochemical test uses antibodies that recognize human hemoglobin specifically, so red meat and vegetables do not interfere with it, unlike the older guaiac-based tests. No dietary restriction and no bowel prep are required.
Will this show up on my regular blood work?
No. It is a separate examination performed on stool and reported on its own. That said, iron-deficiency anemia discovered on a routine blood panel can itself point to digestive bleeding and prompt an evaluation of the gut, independently of any screening program. An panel de estudios sobre el hierro is often the next step.
What if I had a colonoscopy recently?
A recent normal colonoscopy resets the clock. Your clinician will tell you when the next examination is due, typically far longer than a year away, and you generally do not need annual stool testing in the interval.
Glosario
- Fecal immunochemical test (FIT): a test that detects human hemoglobin in stool using specific antibodies.
- Occult blood: blood present in amounts too small to be seen with the naked eye.
- Positivity threshold: the hemoglobin concentration above which a test is reported as positive.
- Polyp: a growth on the bowel lining, usually benign, that can turn cancerous over years if left in place.
- Adenoma: a type of polyp with the potential to become cancer; its detection rate is a standard quality measure for endoscopists.
- Colonoscopy: examination of the colon with a flexible camera, which allows lesions to be seen and removed in the same session.
- Advanced precancerous lesion: an abnormality that is not cancer but carries a meaningful risk of becoming one.
- Iron-deficiency anemia: a shortage of red blood cells caused by low iron, sometimes the first clue to silent digestive bleeding.
Make sense of your own results
A screening test reported as positive or negative says very little on its own. It takes on meaning next to your complete blood count, your ferritin, your inflammatory markers and the rest of your panel — all delivered on a report full of units and reference ranges that do not explain themselves. AI DiagMe reads your entire lab report and explains, line by line, what each result means in your situation. Upload your report at aidiagme.com para entenderlo con claridad antes de tu próxima consulta.
Lecturas adicionales
- Cáncer colorrectal: síntomas, cribado y tratamiento
- CEA Blood Test: Understanding Carcinoembryonic Antigen
- Fecal Lactoferrin Test: What Your Results Mean
- Stool Culture Test: Purpose and Results
- Ova and Parasites Stool Test: Understanding Results
Fuentes
- Karolinska Institutet. Bowel cancer screening could reduce mortality by over 40 per cent. 20 August 2026. news.ki.se
- Blom J, Nyström L, Jonsson H. Fecal Occult Blood Screening Outcomes Adjusted for Contamination Bias and Nonadherence. JAMA Network Open. 20 August 2026. Press release and reference
- US Preventive Services Task Force. Colorectal Cancer: Screening. uspreventiveservicestaskforce.org
- Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: an update to the American Cancer Society guideline, 2026. CA: A Cancer Journal for Clinicians. 2026;76(3):e70083. DOI
- Castells A, Quintero E, Bujanda L, et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV). The Lancet. 2025;405(10486):1231-1239. DOI
- Galoosian A, Dai H, Croymans D, et al. Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years: A Randomized Clinical Trial. JAMA. 2025;334(9):778-787. DOI
- Reuland DS, O’Leary MC, Crockett SD, et al. Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers: A Randomized Clinical Trial. JAMA Network Open. 2024;7(11):e2446693. DOI
- Gerrard AD, et al. Repeat Faecal Immunochemical Testing for Colorectal Cancer Detection in Symptomatic and Screening Patients: A Systematic Review and Meta-Analysis. Cánceres. 2024. Referencia
- Ladabaum U, et al. Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening. Gut. 2026. Referencia
- Zhou Y, et al. Participation and Yield in Multiple Rounds of Colorectal Cancer Screening Based on Fecal Immunochemical Test: A Systematic Review and Meta-Analysis. The American Journal of Gastroenterology. 2024. Referencia
- Butterly L, et al. Association of endoscopist colonoscopy quality measures with follow-up colonoscopy outcomes after positive stool tests. The American Journal of Gastroenterology. 2024. Referencia
